These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23676368)

  • 1. Effectiveness of the direct renin inhibitor, aliskiren, in patients with resistant hypertension.
    Yoshitomi Y; Kawanishi K; Yamaguchi A; Sakurai S; Minai K; Ishii T; Tarutani Y; Tsujibayashi T; Kaneki M; Saitou Y; Suwa S
    Int Heart J; 2013; 54(2):88-92. PubMed ID: 23676368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
    Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.
    Andersen K; Weinberger MH; Egan B; Constance CM; Wright M; Lukashevich V; Keefe DL
    Cardiovasc Ther; 2010 Dec; 28(6):344-9. PubMed ID: 20406241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aliskiren improves blood pressure control and prevents cardiac damage in high-risk hypertensive subjects.
    Mazza A; Montemurro D; Zuin M; Schiavon L; Zorzan S; Chondrogiannis S; Ferretti A; Ramazzina E; Rubello D
    Minerva Cardioangiol; 2013 Aug; 61(4):461-9. PubMed ID: 23846012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
    Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
    J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
    Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Hsu H; Zhang J
    Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An observational, prospective, open-label, multicentre evaluation of aliskiren in treated, uncontrolled patients: a real-life, long-term, follow-up, clinical practice in Italy.
    Tocci G; Aimo G; Caputo D; De Matteis C; Di Napoli T; Granatelli A; Lentini P; Magagna A; Matarrese AA; Perona D; Villa G; Volpe M;
    High Blood Press Cardiovasc Prev; 2012 Jun; 19(2):73-83. PubMed ID: 22867093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
    Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of aliskiren in the management of hypertension and major cardiovascular outcomes: a systematic review and meta-analysis.
    Bjerre HL; Christensen JB; Buus NH; Simonsen U; Su J
    J Hum Hypertens; 2019 Nov; 33(11):795-806. PubMed ID: 30631130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the antihypertensive and anti-inflammatory effects of aliskiren and ramipril add-on therapy in peritoneal dialysis patients--a pilot open label study.
    Makówka A; Olejniczak-Fortak M; Nowicki M
    Kidney Blood Press Res; 2012; 36(1):18-25. PubMed ID: 22777192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial.
    Duprez DA; Munger MA; Botha J; Keefe DL; Charney AN
    J Hum Hypertens; 2010 Sep; 24(9):600-8. PubMed ID: 20033075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of aliskiren in Latin America in a real-world setting: aliskiren in Latin America Study (ALAS).
    Volman S; Benitez FN; Cedenio H; Giorgi M; Jaramillo N; Molina N; Zilberman J
    Ther Adv Cardiovasc Dis; 2013 Aug; 7(4):189-96. PubMed ID: 23723254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
    Yarows SA; Oparil S; Patel S; Fang H; Zhang J
    Adv Ther; 2008 Dec; 25(12):1288-302. PubMed ID: 19066757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of aliskiren and aliskiren hydrochlorothiazide (HCT) in a multiethnic, real-world setting.
    Maddury SR; Pande A; Haque KM; Echtay A; Go L; Gulzar T; Kadwa M; Hristoskova S
    Adv Ther; 2013 Feb; 30(2):176-89. PubMed ID: 23354585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone.
    Blumenstein M; Romaszko J; Calderón A; Andersen K; Ibram G; Liu Z; Zhang J
    Curr Med Res Opin; 2009 Apr; 25(4):903-10. PubMed ID: 19245300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aliskiren, a direct renin inhibitor, in clinical practice: a new approach in the treatment of hypertension.
    Moutzouri E; Florentin M; Elisaf MS; Mikhailidis DP; Liberopoulos EN
    Curr Vasc Pharmacol; 2010 May; 8(3):344-62. PubMed ID: 20180771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood pressure lowering efficacy of renin inhibitors for primary hypertension.
    Musini VM; Fortin PM; Bassett K; Wright JM
    Cochrane Database Syst Rev; 2008 Oct; (4):CD007066. PubMed ID: 18843743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of aliskiren on blood pressure and myocardial function assessed by global longitudinal strain in patients with arterial hypertension and diastolic dysfunction.
    Manov E; Shabani R; Naydenov SN; Runev NM; Donova TI
    Folia Med (Plovdiv); 2012; 54(3):30-4. PubMed ID: 23270204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-responders.
    Nickenig G; Simanenkov V; Lembo G; Rodriguez P; Salko T; Ritter S; Zhang J
    Blood Press Suppl; 2008 Dec; 2():31-40. PubMed ID: 19203020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
    Gradman AH; Schmieder RE; Lins RL; Nussberger J; Chiang Y; Bedigian MP
    Circulation; 2005 Mar; 111(8):1012-8. PubMed ID: 15723979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.